Myasthenia gravis (MG) is mostly related to the abnormal production of autoantibodies directed either against the acetylcholine receptor (ARch) or against the MuSK receptor, and much more rarely against other elements of the neuromuscular junction such as titin. A group of European experts, including two French representatives, one of whom is from the Institute of Myology, has studied the fluctuations of these autoantibodies by sharing their experience and reviewing the literature:
- 42 published studies were of interest to the experts.
- Ten of them reported correlations between autoantibody levels and clinical severity.
- This was particularly true for RAch, anti-MuSK and anti-titin antibodies.
- However, due to the lack of sufficient statistical evidence, the experts do not draw any definite conclusions about the usefulness of such assays in the follow-up of MG patients.
